Back to mobile site
Get it on Google Play

Quoin gets FDA clearance for Phase 2 trial of QRX003 in rare skin disease

July 9, 2026 8:30 AM EDT Send to a Friend
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login